Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone furoate/vilanterol vs BREO ELLIPTA in adult asthma
2025-521565-27-00Phase 3Withdrawn
- Sponsor
- Sandoz
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate + vilanterol in asthma (3 arms), sponsored by Sandoz. Primary endpoints: FEV1 AUC0-24h on the first day of treatment and Trough FEV1 on last day of 4-week treatment. Planned start Sep 2025; status: withdrawn.
02
Drugs
fluticasone propionate + vilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-521565-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521565-27-00.